120 related articles for article (PubMed ID: 31464247)
1. Serum tumor markers in advanced stages of chronic kidney diseases.
Rani BS; Suchitra MM; Srinivasa Rao PVLN; Kumar VS
Saudi J Kidney Dis Transpl; 2019; 30(4):898-904. PubMed ID: 31464247
[TBL] [Abstract][Full Text] [Related]
2. Reference limits for chromogranin A, CYFRA 21-1, CA 125, CA 19-9 and carcinoembryonic antigen in patients with chronic kidney disease.
Mikkelsen G; Åsberg A; Hultström ME; Aasarød K; Hov GG
Int J Biol Markers; 2017 Oct; 32(4):e461-e466. PubMed ID: 28561881
[TBL] [Abstract][Full Text] [Related]
3. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of serum carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 15-3 (CA15-3), alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG) levels in determining the malignancy of solitary pulmonary nodules.
Bekci TT; Senol T; Maden E
J Int Med Res; 2009; 37(2):438-45. PubMed ID: 19383238
[TBL] [Abstract][Full Text] [Related]
5. Impact of chronic kidney disease on serum tumor markers concentrations.
Tong HL; Dong ZN; Wen XY; Gao J; Wang B; Tian YP
Chin Med J (Engl); 2013 Jan; 126(2):274-9. PubMed ID: 23324276
[TBL] [Abstract][Full Text] [Related]
6. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of CA15-3, AFP, CA19-9 and CEA tumor markers in cancer care and treatment of patients with impaired renal function on hemodialysis.
Estakhri R; Ghahramanzade A; Vahedi A; Nourazarian A
Asian Pac J Cancer Prev; 2013; 14(3):1597-9. PubMed ID: 23679242
[TBL] [Abstract][Full Text] [Related]
8. Acquired renal cystic disease and tumor markers in chronic hemodialysis patients.
Polenakovic M; Sikole A; Dzikova S; Polenakovic B; Gelev S
Int J Artif Organs; 1997 Feb; 20(2):96-100. PubMed ID: 9093887
[TBL] [Abstract][Full Text] [Related]
9. Serum tumor markers in hemodialysis patients.
Maoujoud O; El Machtani S; Asseraji M; Atbib Y; Zajjari Y; Taoufik A; Elbouaiti E; Zouhair O; Benyahia M; Tellal S
Int J Artif Organs; 2014 Feb; 37(2):126-32. PubMed ID: 24619900
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of abnormal levels of serum tumour markers in elderly people.
Lopez LA; Del Villar V; Ulla M; Fernandez F; Fernandez LA; Santos I; Rabadan L; Gutierrez M
Age Ageing; 1996 Jan; 25(1):45-50. PubMed ID: 8670528
[TBL] [Abstract][Full Text] [Related]
11. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
Park BW; Oh JW; Kim JH; Park SH; Kim KS; Kim JH; Lee KS
Ann Oncol; 2008 Apr; 19(4):675-81. PubMed ID: 18037623
[TBL] [Abstract][Full Text] [Related]
12. Tumor markers in hemodialysis patients.
Arican A; Ozdemir N; Sezer S; Erten Y; Güz G; Turan M; Inanoglu I; Haberal M
Transplant Proc; 1999 Dec; 31(8):3367-8. PubMed ID: 10616509
[No Abstract] [Full Text] [Related]
13. Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma.
Grankvist K; Ljungberg B; Rasmuson T
Int J Cancer; 1997 Apr; 74(2):233-6. PubMed ID: 9133462
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of a diagnostic score for colon cancer based on serum CEA, CA19-9, cytokeratin-1 and mucin-1.
Attallah AM; El-Far M; Ibrahim AR; El-Desouky MA; Omran MM; Elbendary MS; Attallah KA; Qura ER; Abdallah SO
Br J Biomed Sci; 2018 Jul; 75(3):122-127. PubMed ID: 29734875
[TBL] [Abstract][Full Text] [Related]
15. Significance of serum tumor markers carcinoembryonic antigen, CA 19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation.
Pissaia A; Bernard D; Scatton O; Soubrane O; Conti F; Calmus Y
Transplant Proc; 2009 Mar; 41(2):682-4. PubMed ID: 19328956
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of tumour markers in molar pregnancy.
Hegab HM; Schindler AE; Rizk M; Ramadan M
Arch Gynecol Obstet; 2003 Aug; 268(3):151-4. PubMed ID: 12942241
[TBL] [Abstract][Full Text] [Related]
17. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885
[TBL] [Abstract][Full Text] [Related]
18. Human chorionic gonadotropin and CA 15-3 producing adenocarcinoma.
Uçkaya G; Ozet A; Arpaci A; Kömürcü S
Nuklearmedizin; 1998; 37(8):297-8. PubMed ID: 9868713
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
20. Clinical Evaluation of Serum Tumor Markers in the Diagnosis of Gastric Adenocarcinoma Staging and Grading.
Ghaderi B; Moghbel H; Daneshkhah N; Babahajian A; Sheikhesmaeili F
J Gastrointest Cancer; 2019 Sep; 50(3):525-529. PubMed ID: 29806060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
